. 2013 Nov 18;2(4):186–195. doi: 10.1530/EC-13-0046
This work is licensed under a Table 3.
Diagnostic value (%) of the presence of CDC73 mutation and loss of parafibromin immunostaining in the diagnosis of parathyroid carcinomaa.
| CDC73 mutationb | Loss of parafibrominc | |
|---|---|---|
| Sensitivity (95% CI) | 41 (24–59) | 50 (32–68) |
| Specificity (95% CI) | 95 (77–99) | 95 (77–92) |
| Positive predictive value (95% CI)d | 4 (0–10) | 5 (0–12) |
| Negative predictive value (95% CI)d | 100 (98–100) | 100 (98–100) |
a
A series of 22 parathyroid adenomas previously characterized for CDC73 mutations and parafibromin immunostaining was used as a control (Cetani et al. (12)).
b
CDC73 mutational data were available in 32 patients.
c
Parafibromin immunostaining data were available for 34 patients.
d
Positive and negative predictive values are calculated given the estimated prevalence of parathyroid carcinoma at our Institution of 0.5% among patients with primary hyperparathyroidism.